Jonathan S. Schulman
- Denver
- New York
Jonathan provides experienced advice to clients engaged in sophisticated capital markets transactions and corporate governance matters.
Jonathan Schulman advises public companies in capital markets transactions and in connection with their U.S. Securities and Exchange Commission (SEC) disclosure obligations and related corporate governance matters.
Jonathan represents clients in a variety of capital markets transactions, including initial public offerings, underwritten equity and debt offerings, Rule 144A debt offerings, convertible note offerings, and private placements. Jonathan serves as a trusted advisor to public companies on SEC reporting, compliance and disclosure issues, stock exchange rules, and general corporate matters. Jonathan also represents public companies in mergers and acquisitions.
Areas of focus
Education & Credentials
Education
- University of Virginia School of Law, J.D., Editorial Board, Virginia Law & Business Review, 2014
- University of Miami, B.B.A., Entrepreneurship, summa cum laude, 2010
Bar and Court Admissions
-
Colorado
-
New York
Related Employment
- Latham & Watkins LLP, New York, NY and Washington, D.C., Associate, 2014-2018
- Latham & Watkins LLP, New York, NY, Summer Associate, 2013
Professional Recognition
Recognized by Best Lawyers: Ones to Watch for Corporate Law, 2024-2025
Insights
News
Professional Experience
Capital Markets & Corporate Finance
Crocs
Represented Crocs in multiple Rule 144A senior notes offerings.
Crocs
Represented Crocs in a block trade of its common stock.
Amcor
Represented Amcor in multiple senior notes offerings.
Gevo
Represented Gevo in multiple follow-on common stock and warrant offerings.
CAI International
Represented CAI International in multiple preferred stock offerings.
Ideal Power
Represented Ideal Power in multiple follow-on offerings.
Fate Therapeutics
Represented the underwriters in multiple follow-on offerings of Fate Therapeutics.
Other Offerings
Representation of other various issuers and underwriters in connection with initial public offerings, underwritten public offerings, private investment in public equity (PIPEs), private placements and other financing transactions.
Mergers & Acquisitions
Crocs
Represented Crocs (Nasdaq: CROX) in its $2.5 billion acquisition of HEYDUDE.
Pacira BioSciences
Represented Pacira BioSciences (Nasdaq: PCRX) in its acquisition of Flexion Therapeutics (Nasdaq: FLXN).
CAI International
Represented CAI International (NYSE: CAI) in its acquisition by Mitsubishi HC Capital.
Pacira BioSciences
Represented Pacira BioSciences (Nasdaq: PCRX) in its acquisition of MyoScience.
SMTC Corporation
Represented SMTC Corporation (Nasdaq: SMTX) in its acquisition by H.I.G. Capital.
AeroGrow
Represented AeroGrow (OTC: AERO) in its acquisition by Scotts Miracle-Gro (NYSE: SMG).
Peak Resorts
Represented Peak Resorts (Nasdaq: SKIS) in its acquisition by Vail Resorts (NYSE: MTN).